Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.45 |
| ▸ | CCR5 | P51681 | 2/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.42 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6408401 | 0.99 | PPARG (0.44) | PPARGCCR5CCR2LIPGUTS2R | |
| SCHEMBL6411490 | 0.92 | UTS2R (0.52) | PPARGCCR5CCR2UTS2RROCK2 | |
| SCHEMBL6411492 | 0.91 | UTS2R (0.48) | PPARGCCR5CCR2UTS2RROCK2 | |
| SCHEMBL6409516 | 0.91 | UTS2R (0.46) | PPARGCCR5CCR2UTS2RROCK2 | |
| Hydrochloric Acid SCHEMBL6411234 | 0.91 | UTS2R (0.51) | PPARGCCR5CCR2UTS2RROCK2 | |
| Hydrochloric Acid SCHEMBL6409988 | 0.91 | UTS2R (0.48) | PPARGCCR5CCR2UTS2RROCK2 | |
| Hydrochloric Acid SCHEMBL6411353 | 0.90 | UTS2R (0.45) | PPARGCCR5CCR2UTS2RROCK2 | |
| SCHEMBL6416207 | 0.89 | CCR5 (0.46) | CCR5CCR2LIPG | |
| SCHEMBL6409706 | 0.89 | UTS2R (0.44) | PPARGLIPGUTS2RROCK2ROCK1 | |
| SCHEMBL6409386 | 0.89 | PPARG (0.43) | PPARGCCR5CCR2UTS2RROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | PPARG 171/4885CCR5 4/4885CCR2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.